This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

New study identifies predictive signature for prognosis and immunotherapy of lung squamous cell carcinoma (LUSC)

May 3rd, 2023
New study identifies predictive signature for prognosis and immunotherapy of lung squamous cell carcinoma (LUSC)
Expression levels of cuproptosis-related lncRNAs in LUSC patients. The levels of AC002467.1 and LINC01740 were higher in LUSC tissues compared with normal tissues, and the level of LINC02345 was lower in LUSC tissues. lncRNA: Long non-coding RNA; LUSC: Lung squamous cell carcinoma. Credit: Biomolecules and Biomedicine (formerly, the Bosnian Journal of Basic Medical Sciences, BJBMS)

The authors from The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China, investigated the association between cuproptosis, a copper-induced mechanism of mitochondrial-related cell death, and long non-coding RNA (lncRNA) in lung squamous cell carcinoma (LUSC). Cuproptosis has shown potential in cancer treatment, and lncRNAs have been found to play a role in changing the biological activities of tumor cells. Until now, it was not known whether lncRNAs were associated with cuproptosis in LUSC.

LUSC is one of the most difficult tumors to treat, and the authors aimed to develop a signature based on cuproptosis-associated lncRNAs that could predict the prognosis of LUSC and investigate the immunological characteristics of LUSC. The study analyzed 49 normal samples and 502 tumor samples obtained from online databases. The researchers found that a signature consisting of three cuproptosis-related lncRNAs: AC002467.1, LINC01740, and LINC02345, could accurately predict the prognosis of patients with LUSC. Additionally, they used the signature to assess the prognostic risk of patients with LUSC and found that individuals with low-risk scores may benefit from immunotherapy.

The study also found that patients with LUSC who had more mutated risk genes in their bodies had a worse prognosis. These findings suggest that the predictive model based on the three identified lncRNAs is a satisfactory indicator for assessing the prognosis and immunotherapy of LUSC.

The study's lead authors expressed hope that these findings would lead to further research in drug development against LUSC based on the identified lncRNAs. "I believe it will be very exciting to see the results when they become available," Qing Lou stated.

The study's findings have important implications for cancer research and treatment and offer hope for improving outcomes for patients with LUSC.

More information:
Chunlan Hou et al, A cuproptosis-associated long non-coding RNA signature for lung squamous cell carcinoma prognosis and immunotherapy, Biomolecules and Biomedicine (2023). DOI: 10.17305/bb.2022.8481

Provided by Association of Basic Medical Sciences of FBIH

Citation: New study identifies predictive signature for prognosis and immunotherapy of lung squamous cell carcinoma (LUSC) (2023, May 3) retrieved 21 August 2025 from https://sciencex.com/wire-news/444551154/new-study-identifies-predictive-signature-for-prognosis-and-immu.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
Back to list